Allergan Launches Generic Version of INVEGA® (paliperidone)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
Guggenheim Reiterates Buy on Allergan (AGN) Following Updated Guidance
September 29, 2015 8:04 AM EDTGuggenheim reiterated a Buy rating and $400.00 price target on Allergen (NYSE: AGN) following updated 2H15 guidance. The guidance excludes the generics business AGN plans to divest to TEVA (NEUTRAL, $56.90) by 1Q16, but includes all of AGN's interest expense.
Analyst Louise Chen commented, "After... More
RBC Capital Cuts Price Target on Allergan (AGN) Following 2H15 Guidance
September 29, 2015 7:22 AM EDTRBC Capital maintained an Outperform rating on Allergen (NYSE: AGN), and cut the price target to $354.00 (from $375.00), after the company provided its anticipated 2H2015 "continuing operations" guidance. AGN provided 2H2015E revenue of >$8 billion, EBIT of $3.8 to $4.0 billion and EPS of $6.25 to $6.65.
Analyst Randall... More
Allergan (AGN) Launches Generic INVEGA
September 25, 2015 8:08 AM EDTAllergan plc (NYSE: AGN) launched a generic version of Janssen's INVEGA the U.S. Allergan is the first company to receive FDA approval for and launch a generic version of INVEGA®, demonstrating the deep expertise of the Company's global generics R&D, regulatory and... More
